Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      JnJ recalls surgical staplers due to potential failure; USFDA terms it as severest

      JnJ recalls surgical staplers due to potential failure; USFDA terms it as severest

      Farhat Nasim20 May 2019 9:30 AM IST
      JnJ Ethicon unit confirmed serious injuries to two patients, related to the use of the recalled product, the FDA said.U.S: The U.S. Food and Drug...
      Pfizer gets USFDA approval for Fragmin to treat blood clot in pediatric patients

      Pfizer gets USFDA approval for Fragmin to treat blood clot in pediatric patients

      Farhat Nasim19 May 2019 9:45 AM IST
      The efficacy of Fragmin in children was based on a single trial with 38 pediatric patients with symptomatic deep vein thrombosis and/or pulmonary...
      Aurobindo Pharma: USFDA designates 3 facilities as Official Action Indicated

      Aurobindo Pharma: USFDA designates 3 facilities as 'Official Action Indicated'

      Farhat Nasim18 May 2019 10:00 AM IST
      Aurobindo Pharma is confident these OAI classifications would not have an impact on the disruption of supplies or revenue from operations of these...
      Cipla gets no USFDA observations for Indore facility

      Cipla gets no USFDA observations for Indore facility

      Farhat Nasim18 May 2019 9:45 AM IST
      The US health regulator conducted a post-approval inspection at Cipla Ltd's Indore facility from 13th May to 17th May 2019. New Delhi: Drug firm Cipla...
      Its All In The Name: State drug regulators told to BAN marketing of new formulations in old brand names

      Its All In The Name: State drug regulators told to BAN marketing of new formulations in old brand names

      Farhat Nasim17 May 2019 5:37 PM IST
      New Delhi: In a major setback to many pharma companies in the country, the ruling Government is reported to have directed state drug controllers to...
      Shilpa Medicare gets USFDA nod for Irinotecan injection to treat cancer

      Shilpa Medicare gets USFDA nod for Irinotecan injection to treat cancer

      Farhat Nasim17 May 2019 1:45 PM IST
      Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum, the company added. NEW DELHI: Shilpa...
      Lupin reviews details of US lawsuit on drug price manipulation

      Lupin reviews details of US lawsuit on drug price manipulation

      Farhat Nasim17 May 2019 9:30 AM IST
      "We have received a copy of the lawsuit filed against the generic drug manufacturers and are reviewing details of the same," Lupin Ltd said in a...
      Dr Reddys launches generic version of Cubicin to treat skin infections

      Dr Reddys launches generic version of Cubicin to treat skin infections

      Farhat Nasim16 May 2019 11:24 AM IST
      The company has launched its product Daptomycin, which is a generic version of Merck Sharp & Dohme Corp's Cubicin, after obtaining approval from...
      Lupin receives three USFDA observations for Aurangabad facility

      Lupin receives three USFDA observations for Aurangabad facility

      Farhat Nasim16 May 2019 9:45 AM IST
      The US Food and Drug Administration (USFDA) carried out the inspection at the plant from May 6 to May 15, Lupin said in a statement.Mumbai: Drug maker...
      Lupin gets 4 USFDA observations after closure of pharmacovigilance inspection

      Lupin gets 4 USFDA observations after closure of pharmacovigilance inspection

      Farhat Nasim15 May 2019 9:45 AM IST
      The inspection was conducted at its global pharmacovigilance group DSRM (Drug Safety & Risk Management) based out of Mumbai between January 14-18,...
      Inflated prices to 1000 per cent; Lupin, Sun Pharma, Dr Reddys, others face lawsuit

      Inflated prices to 1000 per cent; Lupin, Sun Pharma, Dr Reddys, others face lawsuit

      Farhat Nasim14 May 2019 4:57 PM IST
      Mumbai: In a major setback, a group of domestic pharmaceutical companies including Zydus Cadila, Lupin, Aurobindo Pharma, Dr Reddy's Labs, Wockhardt,...
      Glenmark Pharma gets USFDA nod for generic version of Nexium to treat acid reflux

      Glenmark Pharma gets USFDA nod for generic version of Nexium to treat acid reflux

      Farhat Nasim14 May 2019 10:30 AM IST
      The approved products Esomeprazole Magnesium delayed-release capsule is a generic version of AstraZeneca Pharmaceuticals' Nexium delayed-release...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok